Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
AstraZeneca’s Farxiga was granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the diabetes drug and putting the medicine ahead of rivals.
Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.
Researchers from Cold Spring Harbor Laboratory in New York discovered that certain proteins believed essential for the survival of cancer cells – the same proteins that many drugmakers have been targeting – may not be as important after all.
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.
Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.
Amgen drug shrinks lung cancer tumors in half of patients: study
Advanced lung cancer, Cancer Cells, Cancer Deaths, Checkpoint Inhibitors, Chemotherapy, Clinical Data, Clinical Trials, Colorectal Cancer, Genetic Mutations, Immune System, KRAS Mutations, Non-Small Cell Lung Cancer, R&D, Tumor Shrinkage, Wall Street, World Conference on Lung CancerAn experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
The U.S. FDA approved Kyowa Kirin’s Nourianz (istradefylline) as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “off” episodes.
The Food and Drugs Administration is expanding the regulatory agency’s investigation into impurities in U.S. generic drugs beyond a class of hypertension drugs known as angiotensin II receptor blockers (ARBs).
